BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

21704

540701

DCAL

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

DISHMAN CARBO AMCIS LTD performance

Today’s low

Today’s high

₹ 191.36 ₹ 204.87
₹ 193.07

52 week low

52 week high

₹ 133.00 ₹ 307.98
₹ 193.07

Open Price

₹ 202.66

Prev. Close

₹ 202.66

Volume (Shares)

310498.00

Total traded value

₹ 599.47

Upper Circuit

₹ 243.19

Lower Circuit

₹ 162.12

info

DISHMAN CARBO AMCIS LTD Share Price Update

As of the latest trading session, DISHMAN CARBO AMCIS LTD share price is currently at ₹ 193.07, which is down by ₹ -9.58 from its previous closing. Today, the stock has fluctuated between ₹ 191.36 and ₹ 204.87. Over the past year, DISHMAN CARBO AMCIS LTD has achieved a return of -16.83 %. In the last month alone, the return has been -12.42 %. Read More...

DISHMAN CARBO AMCIS LTD fundamentals


  • Market cap (Cr)

    3,027.01

  • P/E Ratio (TTM)

    -90.07

  • Beta

    1.63

  • Book Value / share

    258.01

  • Return on equity

    0.00%

  • EPS (TTM)

    0.00

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    -13.28

info icon alternate text
  • Market cap (Cr)

    3,021.99

  • P/E Ratio (TTM)

    -90.07

  • Beta

    1.55

  • Book Value / share

    258.01

  • Return on equity

    0.00%

  • EPS (TTM)

    0.00

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    -13.28

info icon alternate text

DISHMAN CARBO AMCIS LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 97.04
Operating Expense 108.33
Net Profit -13.28
Net Profit Margin (%) -13.68
Earnings Per Share (EPS) -0.85
EBITDA 14.95
Effective Tax Rate (%) 31.19
Particulars SEP 2024 (Values in Cr)
Revenue 93.29
Operating Expense 111.78
Net Profit 14.25
Net Profit Margin (%) 15.27
Earnings Per Share (EPS) 0.91
EBITDA 37.33
Effective Tax Rate (%) -161.94
Particulars JUN 2024 (Values in Cr)
Revenue 103.41
Operating Expense 120.56
Net Profit -3.47
Net Profit Margin (%) -3.35
Earnings Per Share (EPS) -0.22
EBITDA 26.49
Effective Tax Rate (%) 37.58
Particulars MAR 2024 (Values in Cr)
Revenue 111.26
Operating Expense 141.68
Net Profit -31.12
Net Profit Margin (%) -27.97
Earnings Per Share (EPS) 0.54
EBITDA 8.35
Effective Tax Rate (%) 7.46
Particulars DEC 2023 (Values in Cr)
Revenue 86.82
Operating Expense 127.01
Net Profit -18.18
Net Profit Margin (%) -20.93
Earnings Per Share (EPS) -1.16
EBITDA 16.28
Effective Tax Rate (%) 32.86
Particulars MAR 2024 (Values in Cr)
Revenue 327.35
Operating Expense 490.35
Net Profit -76.41
Net Profit Margin (%) -23.34
Earnings Per Share (EPS) -3.93
EBITDA 66.80
Effective Tax Rate (%) 25.81
Particulars MAR 2023 (Values in Cr)
Revenue 402.55
Operating Expense 548.91
Net Profit -58.87
Net Profit Margin (%) -14.62
Earnings Per Share (EPS) -3.75
EBITDA 57.92
Effective Tax Rate (%) 38.80
Particulars MAR 2022 (Values in Cr)
Revenue 306.61
Operating Expense 444.40
Net Profit -31.55
Net Profit Margin (%) -10.28
Earnings Per Share (EPS) -2.01
EBITDA 93.98
Effective Tax Rate (%) 63.42
Particulars MAR 2021 (Values in Cr)
Revenue 200.32
Operating Expense 428.49
Net Profit -232.81
Net Profit Margin (%) -116.21
Earnings Per Share (EPS) -14.85
EBITDA 13.49
Effective Tax Rate (%) -39.57
Particulars MAR 2020 (Values in Cr)
Revenue 580.74
Operating Expense 594.82
Net Profit 38.52
Net Profit Margin (%) 6.63
Earnings Per Share (EPS) 2.46
EBITDA 243.13
Effective Tax Rate (%) 30.54
Particulars MAR 2024 (Values in Cr)
Book Value / Share 358.90
ROE % -2.68
ROCE % -0.03
Total Debt to Total Equity 0.40
EBITDA Margin 11.80
Particulars MAR 2023 (Values in Cr)
Book Value / Share 370.51
ROE % -0.15
ROCE % 0.97
Total Debt to Total Equity 0.36
EBITDA Margin 14.91
Particulars MAR 2022 (Values in Cr)
Book Value / Share 353.89
ROE % 0.88
ROCE % 0.81
Total Debt to Total Equity 0.30
EBITDA Margin 17.29
Particulars MAR 2021 (Values in Cr)
Book Value / Share 363.45
ROE % -2.98
ROCE % 0.03
Total Debt to Total Equity 0.26
EBITDA Margin 16.23
Particulars MAR 2020 (Values in Cr)
Book Value / Share 364.25
ROE % 2.86
ROCE % 3.69
Total Debt to Total Equity 0.22
EBITDA Margin 26.52
Particulars MAR 2024 (Values in Cr)
Book Value / Share 258.46
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.14
EBITDA Margin 20.41
Particulars MAR 2023 (Values in Cr)
Book Value / Share 262.39
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.14
EBITDA Margin 14.39
Particulars MAR 2022 (Values in Cr)
Book Value / Share 269.88
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.12
EBITDA Margin 30.30
Particulars MAR 2021 (Values in Cr)
Book Value / Share 298.13
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.12
EBITDA Margin 3.41
Particulars MAR 2020 (Values in Cr)
Book Value / Share 305.66
ROE % 0.88
ROCE % 1.98
Total Debt to Total Equity 0.12
EBITDA Margin 42.87
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 413.35
Total Assets 9581.41
Total Liabilities 9581.41
Total Equity 5627.50
Share Outstanding 156783095
Price to Book Ratio 0.91
Return on Assets (%) -1.60
Return on Capital (%) -2.02
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 189.17
Total Assets 9453.50
Total Liabilities 9453.50
Total Equity 5809.67
Share Outstanding 156783095
Price to Book Ratio 0.48
Return on Assets (%) -0.31
Return on Capital (%) -0.39
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 172.09
Total Assets 8637.45
Total Liabilities 8637.45
Total Equity 5548.94
Share Outstanding 156783095
Price to Book Ratio 0.69
Return on Assets (%) 0.20
Return on Capital (%) 0.26
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 307.74
Total Assets 8366.10
Total Liabilities 8366.10
Total Equity 5698.82
Share Outstanding 156783095
Price to Book Ratio 0.37
Return on Assets (%) -1.97
Return on Capital (%) -2.41
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 160.98
Total Assets 8199.81
Total Liabilities 8199.81
Total Equity 5715.06
Share Outstanding 156863095
Price to Book Ratio 0.18
Return on Assets (%) 1.93
Return on Capital (%) 2.39
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 9.90
Total Assets 5076.66
Total Liabilities 5076.66
Total Equity 4052.58
Share Outstanding 156783095
Price to Book Ratio 0.91
Return on Assets (%) -1.50
Return on Capital (%) -1.67
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 68.43
Total Assets 5181.04
Total Liabilities 5181.04
Total Equity 4114.31
Share Outstanding 156783095
Price to Book Ratio 0.48
Return on Assets (%) -1.13
Return on Capital (%) -1.25
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 86.47
Total Assets 5214.31
Total Liabilities 5214.31
Total Equity 4231.78
Share Outstanding 156783095
Price to Book Ratio 0.69
Return on Assets (%) -0.60
Return on Capital (%) -0.66
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 80.32
Total Assets 5551.75
Total Liabilities 5551.75
Total Equity 4674.62
Share Outstanding 156783095
Price to Book Ratio 0.37
Return on Assets (%) -4.19
Return on Capital (%) -4.48
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 65.13
Total Assets 5734.68
Total Liabilities 5734.68
Total Equity 4795.85
Share Outstanding 156863095
Price to Book Ratio 0.18
Return on Assets (%) 0.67
Return on Capital (%) 0.73
Particulars MAR 2024 (Values in Cr)
Net Income -122.26
Cash from Operations 402.94
Cash from Investing -229.52
Cash from Financing -22.15
Net change in Cash 132.30
Free Cash Flow 706.19
Particulars MAR 2023 (Values in Cr)
Net Income -54.59
Cash from Operations 300.14
Cash from Investing -494.08
Cash from Financing 249.67
Net change in Cash 21.55
Free Cash Flow 919.81
Particulars MAR 2022 (Values in Cr)
Net Income -4.25
Cash from Operations 411.18
Cash from Investing -618.53
Cash from Financing 130.38
Net change in Cash -133.30
Free Cash Flow 874.98
Particulars MAR 2021 (Values in Cr)
Net Income -65.03
Cash from Operations 563.86
Cash from Investing -380.02
Cash from Financing -11.04
Net change in Cash 121.60
Free Cash Flow 929.89
Particulars MAR 2020 (Values in Cr)
Net Income 197.20
Cash from Operations 659.54
Cash from Investing -441.74
Cash from Financing -97.78
Net change in Cash 45.62
Free Cash Flow 1068.10
Particulars MAR 2024 (Values in Cr)
Net Income -103.00
Cash from Operations 25.39
Cash from Investing 96.57
Cash from Financing -130.76
Net change in Cash -10.02
Free Cash Flow 61.53
Particulars MAR 2023 (Values in Cr)
Net Income -96.20
Cash from Operations -49.35
Cash from Investing 40.71
Cash from Financing 1.38
Net change in Cash -10.81
Free Cash Flow 73.88
Particulars MAR 2022 (Values in Cr)
Net Income -84.39
Cash from Operations 233.48
Cash from Investing -172.67
Cash from Financing -46.16
Net change in Cash 8.52
Free Cash Flow 272.48
Particulars MAR 2021 (Values in Cr)
Net Income -168.69
Cash from Operations 5.67
Cash from Investing 62.07
Cash from Financing -70.53
Net change in Cash -9.97
Free Cash Flow 53.24
Particulars MAR 2020 (Values in Cr)
Net Income 55.46
Cash from Operations 214.94
Cash from Investing -74.30
Cash from Financing -124.07
Net change in Cash -1.67
Free Cash Flow 285.45
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

DISHMAN CARBO AMCIS LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
193.07 -4.73 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 201.70
  • 26 Days 209.50
  • 10 Days 204.70
  • 50 Days 215.30
  • 12 Days 205.50
  • 100 Days 220.20
  • 20 Days 207.90
  • 200 Days 215.20
204.79 PIVOT

First Support

200.74

First Resistance

207.59

Second Support

197.94

Second Resistance

211.64

Third Support

193.89

Third Resistance

214.44

RSI

43.89

ADX

6.91

MACD

-3.06

Williams % R

-39.55

Commodity Channel Index (CCI)

-50.95

Date

2025-04-30

Week

150326.00

Same Day

158814.00

Month

153922.00

1 Year

1.64

3 Year

1.34

Over 1 Month

-12.42%

down

Over 1 Year

-16.83%

down

Over 3 Months

-15.68%

down

Over 3 Years

6.09%

down

Over 6 Months

1.90%

down

Over 5 Years

18.19%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

DISHMAN CARBO AMCIS LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
29.93%
Promoter Holdings
59.32%
FII
9.49%
DII
1.25%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Adimans Technologies Llp 9.3002442E7 (59.32%) Shareholding of Promoter and Promoter Group
Mukul Mahavir Agrawal 8617000.0 (5.5%) Public Shareholding
Hbm Healthcare Investments (cayman) Ltd 5594651.0 (3.57%) Public Shareholding
Massachusetts Institute Of Technology 3562000.0 (2.27%) Public Shareholding
Janmejay Rajnikant Vyas - Huf (janmejay R. Vyas - Karta) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Saloni A. Vyas 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Mansi Janmejay Vyas 1000.0 (0.0%) Shareholding of Promoter and Promoter Group
Aditi Janmejay Vyas 1000.0 (0.0%) Shareholding of Promoter and Promoter Group
Arpit Janmejay Vyas 1000.0 (0.0%) Shareholding of Promoter and Promoter Group
Deohooti Janmejay Vyas 1000.0 (0.0%) Shareholding of Promoter and Promoter Group
Vyas Janmejay R. 1000.0 (0.0%) Shareholding of Promoter and Promoter Group
Mansi Shodhan Family Trust (mansi Shodhan - Trustee) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Aditi Vyas Family Trust (aditi J. Vyas - Trustee) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Arpit Vyas Family Trust (arpit J. Vyas - Trustee) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Deohooti Vyas Family Trust (deohooti J. Vyas - Trustee) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Janmejay Vyas Family Trust (janmejay R. Vyas - Trustee) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Vyas Family Trust (janmejay R. Vyas And Deohooti J. Vyas - Managing Trustees) 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Adiman Ventures 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Discus Solutions Llp 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Zenon Therapeutics Ag 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Aamanya Ag 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Azafran Switzerland Ag 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Armaad Ceuticals Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Creciente Direct Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Rtv Technochem Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Jrv Techpark Pvt Ltd 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Azafran Ventures Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Discus It Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Aham Brahmasmi Entertainment Pvt Ltd 0.0 (0.0%) Shareholding of Promoter and Promoter Group
B R Laboratories Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Leon Hospitality Pvt Ltd 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Dishman Infrastructure Ltd 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Dishman Biotech Ltd 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Azafran Innovacion Ltd 0.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

DISHMAN CARBO AMCIS LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
12 Sep 2019 0.2 Final 14 Sep 2019 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
12 Sep 2019 0.2 Final 14 Sep 2019 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

DISHMAN CARBO AMCIS LTD Share Price

Dishman Carbogen Amcis Limited was formerly incorporated as Carbogen Amcis (India) Limited on July 17, 2007. The Company name later on was changed to Dishman Carbogen Amcis Limited effective from 27 March 2017. The Company is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals and disinfectants with presence in Switzerland, UK, Europe, China and other countries. It has manufacturing and research facilities in India, Switzerland, France, The Netherland and China.

During the financial year ended 31 March 2017, Dishman Pharmaceuticals and Chemicals Limited (DPCL) and Dishman Care Limited were merged with DPCL's subsidiary Carbogen Amcis (India) Limited, with the key objective of business consolidation and simplification of the Group structure. The name of Carbogen Amcis (India) Ltd. was changed to Dishman Carbogen Amcis Ltd. with effect from

Dishman Pharmaceuticals and Chemicals Ltd was incorporated in the year 1983 as a research-oriented organization. The company set up their first manufacturing unit in Naroda for phase Transfer Catalysts. The company earned the status of 'Quat Company' by establishing themselves in the Quat business.

In the year 1995, the company formed a joint venture company with Schtz & Co, Germany called as 'Schutz Dishman Biotech Private Ltd'. They manufacture Chlorhexidine Base, Chlorhexidine HCl, Chlorhexidine Acetate and Chlorhexidine Gluconate solution, for the European market. In the year 1997, the company commenced their production in the unit I at Bavla.

In the year 1998, the company established marketing subsidiaries Dishman Europe in London and Dishman USA in Middlesex New Jersey. In the year 2001, they signed the first contract-manufacturing project. The company converted their entire Bavla facility into 100% Export oriented Unit in the year 2003. Also, they acquired Chemconserve BV in Netherland.

In April 2004, the company incorporated a wholly owned subsidiary company namely Dishman International Trade (Shanghai) Co Ltd in China. Also, they incorporated Dishman FZE, a wholly owned subsidiary company at Jebel Ali Free Zone in Dubai in July 2004.

During the year 2004-05, the company entered into an agreement with a leading British company NU SCAAN, for the development & manufacture of Bulk Actives for Neutraceutical products. The company acquired the business together with the technology basket pertaining to a group of speciality chemical products from C6, a UK company. Also, they acquired a Manchester UK based Contract Research Company, Synprotec DCR Ltd., through their 100% wholly owned UK based subsidiary company Dishman Europe Ltd.

During the year 2005-06, the company signed a Joint Venture and Shareholdes' Agreement with Arab Company for Drug Industries and Medical Appliances, Saudi Pharmaceutical Industries and Medical Appliances Corporation and Takamul Holding Company for Investments for manufacturing 20 API. The company formed a wholly owned subsidiary, Dishman Switzerland Ltd in Switzerland and through this company, they acquired Innovative Ozone Services Inc, a Switzerland based Contract Research Company.

In August 2006, the company acquired the business of Carbogen Amcis AG which is a Switzerland-based process research and low-volume, highvalue API and hypo Potency products manufacturing company. During the year 2006-07, the company formed a wholly owned subsidiary in Switzerland with the name Dishman Pharma Solution AG and an Indian wholly owned subsidiary, Dishman Infrastructure Ltd for the SEZ project. Also, they incorporated a wholly owned subsidiary company with the name Dishman Pharmaceuticals & Chemicals (Shanghai) Co Ltd at Shanghai Chemical Industry Park in China.

In April 2007, the company made a marketing joint venture with Azzurro Corporation of Japan, in the name of Dishman Japan Ltd for marketing products and services of Dishman group as a whole in Japan and South Korea. In October 2007, the company through their subsidiaries acquired fine chemicals, vitamin D and vitamin D analogue business of Solvay Pharmaceuticals BV in Netherland.

During the year 2007-08, the company formed an Indian wholly owned subsidiary, namely Carbogen Amcis (India) Ltd with an investment of Rs 5 lakhs. In April 2008, they established a wholly owned subsidiary with the name Dishman Australasia Pty. Ltd in Australia.

The new plant at Shanghai Chemical Zone is under construction. The commercial production is expected during the financial year 2008-09. The company has completed the installation of three API units at their Bavla facility and the fourth one will commenced their operation during the financial year 2008-09.

Dishman Pharmaceuticals and Chemicals' (DPCL) state of the art Hi-Potency (Hi-Po unit) - Unit 9 at Bavla has come in operation during the year ended 31 March 2013. Three or four major Global Pharma majors have already completed safety studies, and regular business has started for this unit. Similarly, during the year under review, the Vitamin D3 unit has also commenced operations.

DPCL started a new vertical viz. Generic API during the year under review. The idea is to take the advantage of several products already developed by the company in the form of around 25 to 30 potential good generic APIs for which the company has enough data available to immediately file the DMFs in the regulated market.

DPCL has established a joint venture company namely Dishman Arabia Ltd. (50% holding by company) in Saudi Arabia. Subsequently, due to non-availability of required infrastructure and other related issues, the JV could not take off and decided for voluntary liquidation of the said JV. A Liquidator was appointed to sell of the assets of the Company. The main assets of the Company consisted of the piece of land, which was acquired to establish the production facility. During the year, liquidator has sold JV's land and the Company will be receiving Rs 1.50 crores (approx.) towards sale proceeds.

Dishman Pharmaceuticals and Chemicals' (DPCL) wholly owned subsidiary - Carbogen Amcis AG Switzerland, which is operating in the CRAMS segment through its plant located in Switzerland and UK, has done very well during the financial year ended 31 March 2014. Carbogen Amcis has expanded its markets significantly and also improved the product basket.

In February 2014, DPCL won a mandate from a U.S.-based mid-sized Pharmaceutical customer with 20 kg mfg valued at US$ 1.2 million.

DPCL has upped the ante in cross selling its multiple broad-based capabilities across geographies and in leveraging fresh opportunities wherever possible. It has established a joint Global Sales team that now projects the Group as 'One Company - Two Brands' under the Carbogen Amcis and Dishman brands. As a result of this cross-selling approach, the company's sales team was able to win a new order in the non-potent Oncology space valued at US$ 20 million.

Three or four major Global Pharma majors have already completed safety studies, and regular business has started for DPCL's state-of-the-art Hi-Potency (Hi-Po unit) - Unit 9 at Bavla.

DPCL has firmed up a very effective plan for turning around Dishman China and the actual implementation of this plant started from the last quarter of FY2013-14.

Dishman Pharmaceuticals and Chemicals' (DPCL) CRAMS business was back on the growth path in 2014-15. During the year, DPCL added 10-15 small biotech clients. The company's 100% wholly owned subsidiary - CARBOGEN AMCIS AG Switzerland (CAAG), which is operating in the CRAMS segment through its plant located in Switzerland and UK, has done quite well during the financial year ended 31 March 2015. During the year under review, the China facility has been put under the management of CAAG to cater to their gap of not having large volume manufacturing. Post taking over of the operations of China plant by CAAG, the China unit's performance has improved and the losses have considerably reduced.

During FY 2014-15, Dishman Group has also made remarkable progress specifically in terms of the Oncology space, thanks to the focused hard work in the development process by partnering with many Oncology companies over last few years. Thus Dishman Group bagged a prestigious order for supply of high value added Oncology API for a highly effective Lung Cancer drug to a leading mid size Oncology Formulation company based out of US.

The Octenadine Compound, launched during the year under review, received excellent market response. The company's state-of-the-art Hi-Potency (Hi-Po unit) - Unit 9 at Bavla has performed well during the year under review.During the year under review Dishman Japan Ltd. became wholly owned subsidiary of the Dishman Pharmaceuticals and Chemicals. During the year, Shanghai Yiqian International Trade Co. Ltd. was formed by DPCL's wholly owned subsidiary company Shanghai International Trading Co. Ltd.

During FY 2015, DPCL made Rs 183.42 crore debt repayment by utilising cash accruals.

The Board of Directors of Carbogen Amcis (India) Ltd at their meeting held on 24 February, 2016 approved a Scheme of Arrangement and Amalgamation amongst the company; Dishman Pharmaceuticals and Chemicals Limited (DPCL); Dishman Care Limited (DCL) and their respective shareholders and Creditors (Scheme) in terms of the provisions of Section 391 to 394 of the Companies Act, 1956. The Rationale of the Scheme, amongst others was to consolidate the business so as to provide a high level of synergistic integration, better operational management and provide value addition. It re-emphasizes the strategy of 'One Company, Two Brands' with both 'Dishman' and 'Carbogen Amcis' brands being reflected in one company.

The appointed date for the Scheme was 1 January 2015. The Hon'ble High Court of Gujarat, vide its order dated 16th December, 2016 sanctioned the Scheme. The Scheme has become effective upon filing of certified copy of said order of Hon'ble High Court with the Office of Registrar of Companies, Gujarat/MCA on 17th March, 2017 (Effective Date). DPCL as a going concern stands amalgamated with the company with effect from the Appointed Date i.e. 1st January, 2015. Subsequently, in terms of the said Scheme, the name of company was changed to Dishman Carbogen Amcis Ltd. w.e.f. 27th March, 2017 vide fresh certificate of Incorporation pursuant to change of name issued by the Office of Registrar of Companies, Gujarat. Upon scheme became effective, 2,50,000 equity shares of the company held by DPCL have been stand cancelled and extinguished without consideration.

During the financial year ended 31 March 2017, Dishman Carbogen Amcis performed exceedingly well by achieving increase in revenues as well as improvement of profitability parameters. This was made possible by increase in sales in CRAMS segment, achieving operational efficiencies, reduction in costs and consciously reducing the sales of low-margin products. The company started focusing on five key therapeutic areas, which are namely, oncology, ophthalmic, cardiovascular, CNS and drugs under orphan category. The reason for choosing these five therapies was largely driven by the idea of working towards addressing the unmet needs of the society. During the year, one of the life-saving oncology drugs, for which the company was doing development work on the API since last ten years, received the approval from the US FDA, which was a significant landmark in the history of the company.

The company's CRAMS segment across India, Switzerland, France, UK and China manufacturing facilities has performed very well during the year under review on account of addition of new clients, new molecules and increase in repeat business from existing customers.

The company's subsidiary Carbogen Amcis AG acquired a building in Switzerland so that it does not have to reject orders just on account of development capacity constraint. This building is expected to be operational from the end of first quarter of FY 2019. Once the building is operational, the development revenues of Carbogen Amcis are expected to increase significantly over a period of time.

The API for one of the significant formulated product of the customer, which received approval from the US FDA in the last financial year, was successfully developed in the HiPo facility. The API which was successfully developed in the HiPo Plant was developed initially at the company's Swiss facility and then the molecule along with its technology was successfully migrated to the company's HiPo unit in India in the later phases of development work.

Dishman Carbogen Amcis filed Drug Master File for one niche generic API, which is an imaging dye to detect lymphatic cancer in the very early phase.The Board of Directors of erstwhile Dishman Pharmaceuticals and Chemical Ltd. (DPCL) in its meeting held on 24 February 2016 recommended a Bonus issue of Equity shares in the ratio of 1 (one) equity share for every 1 (one) equity share held, as on the record date to be determined by the Board. On 5 May 2016, DPCL has issued and allotted 8,06,97,136 equity shares of Rs.2/- each, as fully paid-up bonus shares in the ratio of 1 (one) equity share for every 1 (one) equity share held to those shareholders whose names appear in the Register of Members / List of Beneficial owners as on the Record Date i.e. on May 3, 2016.

On 13 July 2016, Dishman Carbogen Amcis formed a new wholly owned subsidiary company namely Dishman Carbogen Amcis (Singapore) Pte. Ltd. in Singapore.

On 30 September 2016, erstwhile DPCL sold 50% stake of Dishman Biotech Ltd. (DBL), a subsidiary of DPCL to Mr. Janmejay R. Vyas. Earlier, DPCL was holding 72.33% stake in DBL and after selling of 50% stake, DBL ceased to be a subsidiary of DPCL and became a Joint Venture with a stake of 22.33%. In March 2017, DPCL sold the entire remaining 22.33% stake of DBL to Mr. Janmejay R. Vyas, Mrs. Deohooti J. Vyas, Ms. Aditi J. Vyas, Ms. Mansi J. Vyas and Mr. Arpit J. Vyas at the price of Rs.30/- per share.

In March 2017, DPCL sold its whole stake of 40% aggregating to 4,000 equity shares of Bhadra Raj Holding Pvt. Ltd. (BHPL), Associate Company of DPCL to Mr. Janmejay R. Vyas and Mrs. Deohooti J. Vyas at a value of Rs.4,161.76 per share.

On 10 March 2017, one of the wholly owned subsidiary viz. Cohecie Fine Chemicals B. V. (formerly known as Dishman Holland B.V.) was struck off/wound-up. Also, Bhardr-Raj Holdings Pvt. Ltd. and Dishman Biotech Ltd., has been discontinued to be an associate and joint venture company due to sale of investment by DPCL of the said companies.

During the year, erstwhile DPCL has sold its whole stake of 0.01% being 130 shares (face value of Rs 10 each) of B.R. Laboratories Ltd. to Mr. Janmejay R. Vyas, Mrs. Deohooti J. Vyas, Ms. Aditi J. Vyas, Ms. Mansi J. Vyas and Mr. Arpit J. Vyas at a value of Rs.7.22 per share.

During the year, erstwhile DPCL has sold its whole stake of 1% being 50,000 shares (face value of Rs 10 each) of Dishman Infrastructure Ltd., to Mr. Janmejay R. Vyas at a value of Rs.91.87 per share.

During the year under review, as a part of global restructuring process, erstwhile DPCL has decided to transfer its 100% investment held in CARBOGEN AMCIS (Shanghai) Co. Ltd., China to its another wholly owned subsidiary company namely Dishman Carbogen Amcis (Singapore) Pte. Ltd., by way of a share swap arrangement for a consideration of RMB 189.51 million. Further, Dishman Carbogen Amcis (Singapore) Pte. Ltd., Singapore (DCASPL) intends to transfer the shares of CASCL to the company's wholly owned subsidiary CARBOGEN AMCIS Holding AG. Switzerland, by way of share swap. This will help the company in realigning the operations globally and ensure a more leaner and logical business structure.

During the financial year ended 31 March 2018, Dishman Carbogen Amcis reinforced its philosophy of working towards achieving the vision of developing and manufacturing novel drugs, which are niche in nature and are able to address the world requirements by making the drugs available on an affordable and sustainable basis. The company's focus was to ensure that the operating margins are sustained in the financial year ending 31 March 2018 in spite of adverse macro and micro economic factors. Moreover, the company targeted to improve the net profit margin, which it was able to achieve due to sustained efforts on reducing the finance cost and bringing in operational efficiencies. All key business verticals of the company and also all major subsidiaries of the company have performed exceedingly well.With regard to its Contract Research And Manufacturing Services (CRAMS) business segment, one of the life-saving oncology drugs, which received the approval from the US FDA in FY 2017, received approval from the EU in FY 2018, which reinforces the strong technical know-how within the group. The CRAMS segment across all locations has performed very well during the year under review on account of addition of new clients, new molecules and increase in repeat business from existing customers.

The company's subsidiary Carbogen Amcis AG commenced incurring capital expenditure on the new building it acquired in January 2017, for modification of the building to meet its developmental project requirements. This capital expenditure is part of group's year 2020 strategy and the company expects the phase I of the expenditure for this building to be completed by Q1 of FY 2018-19. This will help Carbogen Amcis AG to take additional orders for development work and increase the pipeline of products under development, thus increasing the chances of more molecules getting commercialized.

During the year ended 31 March 2018, Dishman Carbogen Amcis improved capacity utilisation at its manufacturing facilities by focusing more on small and mid-sized global biotech companies. The company diversified across new geographies, besides increasing penetration in the US market and leveraging cross-selling opportunities. During the year, the company churned existing capacities better by focusing more on low-volume, high-value orders. The company's profitability margin improved with value-added order execution from Vitamin D analogues facility at Netherlands.

On 6 June 2017, Dishman Carbogen Amcis issued and allotted 16,13,94,272 equity shares of Rs. 2/- each, as fully paid-up equity shares to the shareholders of erstwhile Dishman Pharmaceuticals and Chemicals Limited in the ratio of 1 (one) share of Dishman Carbogen Amcis Limited for every 1 (one) share held in erstwhile Dishman Pharmaceuticals and Chemicals Limited to those shareholders whose names appear in the Register of Members / List of Beneficial owners as on the Record Date i.e. on 31 May 2017, pursuant to the Scheme of arrangement and amalgamation. Trading of Dishman Carbogen Amcis shares on BSE and NSE commenced on 21 September 2017.

During the last quarter of FY 2018, Dishman Carbogen Amcis has initiated the procedure to struck-off/ wound-up of its two dormant wholly owned subsidiaries namely Innovative Ozone Services Inc. (I03S) and Dishman Switzerland Ltd. Also, as reported last year, as a part of global restructuring process, during the year, Dishman Carbogen Amcis has transferred its 100% stake in CARBOGEN AMCIS (Shanghai) Co. Ltd. (CASCL) to its another wholly owned subsidiary namely Dishman Carbogen Amcis (Singapore) Pte. Ltd. (DCASPL) by way of share swaps arrangement for a consideration of RMB 189.51 million. Further, DCASPL has transferred its stake in CASCL to Dishman Carbogen Amcis' wholly owned subsidiary namely CARBOGEN AMCIS Holding AG., Switzerland (CAHAG), by way of share swap. After, this restructuring, Dishman Carbogen Amcis' stake in CAHAG has been reduced to 91.50% and remaining 8.50% has been held by DCASPL.

During the year 2019, name of wholly owned subsidiary company viz. Dishman Netherland B. V. has been changed to CARBOGEN AMCIS B. V.

In 2019-20, the Company acquired Solvay Pharmaceuticals' Veenendaal, Netherlands plant which focused on manufacturing cholesterol, serving as a precursor to vitamin D & its analogues. Further, the Company acquired 100% shareholding in Dishman Biotech Ltd and made it the wholly owned subsidiary of the Company. A new step-down subsidiary company, 'CARBOGEN AMCIS SPECIALITIES AG' was incorporated in Switzerland on 26th September, 2019.

The Identified Disinfectant Undertaking Division of the Company was transferred to the wholly owned subsidiary viz. Invisible Biotech Ltd.(IBL) as a going concern effective from 1st October, 2021 through slump sale in 2021-22.

In 2023, the Company restarted manufacturing of certain APIs, intermediates and Key Starting Materials (KSMs) from its Bavla manufacturing site. Multiple Effect Evaporator (MEE) plant construction started at Naroda site. Powder processing area Line 1 at Naroda site was completed introducing Reverse Laminar Air Flow (RLAF) and pass boxes. A New QC lab at Bavla site was fully qualified and made operational. A new GC-MS (Gaschromatograph-Mass) quadrupole was installed in QC at Bavla site. MEE plant at Bavla site was opened. Erection of the purified water plant was started.

Parent organization Indian Private
NSE symbol DCAL
Founded 2007
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Dishman Carbogen Amcis Ltd?

Answer Field

The share price of Dishman Carbogen Amcis Ltd for NSE is ₹ 193.07 and for BSE is ₹ 192.75.

What is the Market Cap of Dishman Carbogen Amcis Ltd?

Answer Field

The market cap of Dishman Carbogen Amcis Ltd for NSE is ₹ 30,27.01 Cr. and for BSE is ₹ 30,21.99 Cr. as of now.

What is the 52 Week High and Low of Dishman Carbogen Amcis Ltd?

Answer Field

The 52 Week High and Low of Dishman Carbogen Amcis Ltd for NSE is ₹ 307.98 and ₹ 133.00 and for BSE is ₹ 307.80 and ₹ 132.75.

How to Buy Dishman Carbogen Amcis Ltd share?

Answer Field

You can trade in Dishman Carbogen Amcis Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Dishman Carbogen Amcis Ltd?

Answer Field

The 1 year returns on the stock has been -16.83%.

What is the Current Share Price of Dishman Carbogen Amcis Ltd?

Answer Field

Dishman Carbogen Amcis Ltd share price is for NSE ₹ 193.07 & for BSE ₹ 192.75 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Dishman Carbogen Amcis Ltd Share?

Answer Field

The market cap of Dishman Carbogen Amcis Ltd for NSE ₹ 30,27.01 & for BSE ₹ 30,21.99 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Dishman Carbogen Amcis Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Dishman Carbogen Amcis Ltd share is -90.07.

What is the PB ratio of Dishman Carbogen Amcis Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Dishman Carbogen Amcis Ltd share is 258.01.

How to Buy Dishman Carbogen Amcis Ltd Share?

Answer Field

You can trade in Dishman Carbogen Amcis Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Dishman Carbogen Amcis Ltd Share on Bajaj Broking App?

Answer Field

To buy Dishman Carbogen Amcis Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Dishman Carbogen Amcis Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|